Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Jonathan Ian SilverbergCharles W LyndeKatrina AbuabaraCataldo PatrunoAnna De BenedettoHaixin ZhangRyan B ThomasGaëlle Bégo-Le-BagousseFaisal A KhokharJignesh VakilAinara Rodríguez MarcoNoah A LevitPublished in: American journal of clinical dermatology (2023)
ClinicalTrials.gov: NCT02277743, NCT02277769, NCT02755649, NCT02260986. Does dupilumab benefit adults aged 60 years and older with moderate-to-severe atopic dermatitis?(MP4 20,787 KB).